includ class common stock class
look favor upon well plan result report el
morn consist preview last week top- bottom-lin result
well ahead plan share react favor morn constant
currenc sale increas ahead consensu forecast adjust ep
top street figur continu see gain el share
upcom analyst day could repres anoth posit catalyst lift
pt
ep top expect adjust ep el increas
prior year ahead consensu figur
manag guidanc
asia/pacif emea fuel sale upsid constant currenc sale increas
adjust driven strength asia/pacif emea region
constant currenc sale increas asia/pacif emea
decreas america skin care led way constant currenc
sale increas follow hair make-up
manag lift guidanc el expect adjust ep vs
prior guidanc predic adjust constant
lift estim price lift estim primarili
reflect result latest think pt goe
part invest thesi intact pleas see prior research
present key part invest thesi remain intact well
latest note titl el share posit third year out-performance
share latest view name
year price histori el
lauder global manufactur
market skin care make-up
fragranc hair care product
cliniqu bobbi brown
analyst certif import disclosur see disclosur
constant currenc sale earn growth base case
macro environ improv key economi
continu look favor upon longer term
prospect believ compani posit global
prestig beauti categori strong manag team
leadership ceo fabrizio freda consist track record
 front posit compani continu gain market
share near term howev see potenti less upsid
driven strengthen usd increas uncertainti
china given risk relat econom slowdown would
take advantag weak like remain volatil
constant currenc sale earn growth base case
deterior macro environ key countri
competit intensifi el categori
target predic multipl appli june estim target multipl reflect
consider histor trade paramet el above-averag growth prospect vs consum stapl name
risk price target includ increas competit china growth slowdown us depart store challeng acceler
deterior macro environ lower level consum confid chang consum tastes/prefer inabl
innov poor recept new product
fiscal year end june dollar million except per share data
interest expens net
good sold
percentag sale
sg sale
